MedPath

Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer

Registration Number
NCT04452838
Lead Sponsor
Pfizer
Brief Summary

Open Label, Single-Dose, Crossover Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule (BIC) SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administered Intact.

Detailed Description

After oral administration, fesoterodine is not detected in plasma as it is rapidly and extensively hydrolyzed by non-specific esterases to its primary active metabolite 5-hydroxymethyl tolterodine (5-HMT) . Therefore characterization of the rate and extent of absorption of the test and reference fesoterodine formulations will be based on pharmacokinetic parameters of 5-HMT derived from the 5-HMT concentration-time profiles.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
37
Inclusion Criteria

Not provided

Read More
Exclusion Criteria
  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  3. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C antibody (HCVAb). A positive serology for hepatitis B surface antibody (HBsAb) as a result of Hepatitis B vaccination is allowed.
  4. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  5. History of allergy or hypersensitivity to fesoterodine fumarate or tolterodine tartrate, soya, or any of the excipients in the investigational drug product.
  6. History of uncontrolled narrow angle glaucoma, myasthenia gravis, gastric retention, severe ulcerative colitis and toxic megacolon.
  7. Evidence or history of clinically significant urologic disease: urinary retention, obstructive disturbance of bladder emptying, micturition disturbance, nocturia or pollakiuria (eg, benign prostate hyperplasia, urethral stricture, recurrent urinary tract infections).
  8. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
  9. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of investigational product used in this study (whichever is longer).
  10. A positive urine drug test, as confirmed by a single repeat.
  11. Screening supine blood pressure (BP) greater than or equal to 140 mm Hg (systolic) or greater than or equal to 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is greater than or equal to 140 mm Hg (systolic) or greater than or equal to 90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  12. Screening 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline corrected QT (QTc) interval >450 msec, complete left bundle branch block [LBBB], signs of an acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is greater than 450 msec, this interval should be rate-corrected using the Fridericia method and the resulting corrected QT (QTcF) should be used for decision making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
  13. Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:
  14. Screening estimated glomerular filtration rate (eGFR) is less than or equal to 90 mL /min/1.73 m2 for Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula).
  15. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
  16. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  17. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
  18. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Cohort 2 Sequence 1 (Part B)Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)Treatment Sequence E, F, G, and H
Cohort 1 Sequence 1 (Part A)Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)Treatment Sequence A,B,C and D
Cohort 1 Sequence 1 (Part A)Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)Treatment Sequence A,B,C and D
Cohort 2 Sequence 3 (Part B)Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)Treatment Sequence F, E, G, and H
Cohort 2 Sequence 3 (Part B)Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)Treatment Sequence F, E, G, and H
Cohort 2 Sequence 3 (Part B)Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)Treatment Sequence F, E, G, and H
Cohort 2 Sequence 3 (Part B)Fesoterodine BIC SR4 fed (Treatment E in Part B)Treatment Sequence F, E, G, and H
Cohort 2 Sequence 4 (Part B)Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)Treatment sequence F, E, H, and G
Cohort 2 Sequence 4 (Part B)Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)Treatment sequence F, E, H, and G
Cohort 2 Sequence 4 (Part B)Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)Treatment sequence F, E, H, and G
Cohort 2 Sequence 4 (Part B)Fesoterodine BIC SR4 fed (Treatment E in Part B)Treatment sequence F, E, H, and G
Cohort 1 Sequence 2 (Part A)Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)Treatment Sequence B, A,C and D
Cohort 1 Sequence 2 (Part A)Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)Treatment Sequence B, A,C and D
Cohort 1 Sequence 2 (Part A)Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)Treatment Sequence B, A,C and D
Cohort 1 Sequence 2 (Part A)Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)Treatment Sequence B, A,C and D
Cohort 1 Sequence 1 (Part A)Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)Treatment Sequence A,B,C and D
Cohort 1 Sequence 1 (Part A)Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)Treatment Sequence A,B,C and D
Cohort 2 Sequence 1 (Part B)Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)Treatment Sequence E, F, G, and H
Cohort 2 Sequence 1 (Part B)Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)Treatment Sequence E, F, G, and H
Cohort 2 Sequence 1 (Part B)Fesoterodine BIC SR4 fed (Treatment E in Part B)Treatment Sequence E, F, G, and H
Cohort 2 Sequence 2 (Part B)Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)Treatment Sequence E, F, H and G
Cohort 2 Sequence 2 (Part B)Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)Treatment Sequence E, F, H and G
Cohort 2 Sequence 2 (Part B)Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)Treatment Sequence E, F, H and G
Cohort 2 Sequence 2 (Part B)Fesoterodine BIC SR4 fed (Treatment E in Part B)Treatment Sequence E, F, H and G
Primary Outcome Measures
NameTimeMethod
AUCinf of 5-HMT0 (pre dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30, 36, and 48 hours

Area under the plasma concentration-time curve from time zero extrapolated to infinity.

AUClast of 5-HMT0 (pre dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30, 36, and 48 hours

Area under the plasma concentration-time curve from 0 to the time of the last quantifiable concentration.

Cmax of 5-HMT0 (pre dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30, 36, and 48 hours

Maximum Observed Plasma Concentration

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Brussels Clinical Research Unit

🇧🇪

Brussels, Bruxelles-capitale, Région DE, Belgium

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy